2 completed, 1 active not recruiting. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 2 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow AR882 75 mg: new trials by email Literature Review of AR882 75 mg trials Research Report on AR882 75 mg
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Efficacy and Safety of AR882 and XOI Co-administration in Uricase Treatment Failed Patients AR882 75 mg, XOI Low Dose, XOI High Dose - Gout, Gouty Arthritis | Phase 2 | Active not recruiting | Arthrosi Therapeutics | 15 | 2025-12-03 | 2026-05-15 |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-301) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 866 | 2025-03-11 | 2026-09-28 |
| Phase 3 Evaluation of Efficacy and Safety of AR882 in Gout Patients (AR882-302) AR882 50 mg, AR882 75 mg, Placebo - Gout, Arthritis, Gouty | Phase 3 | Completed | Arthrosi Therapeutics | 818 | 2024-06-26 | 2026-10-14 |
Arthritis, Gouty (3) · Gout (3) · Hyperuricemia (3)
United States (3) · Australia (1) · Hong Kong (1) · New Zealand (1) · Taiwan (1)